Quantitative prediction of oral drug interactions caused by CYP3A4 inhibition for an extended panel of substrates and inhibitors

被引：0
|
作者：
Loue, C. [1 ]
Tod, M. [2 ]
机构：
[1] Hop Croix Rousse, F-69317 Lyon, France
[2] Univ Lyon 1, F-69365 Lyon, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2013年 / 27卷
关键词：
drug-drug interaction; cyp3a4; quantitative prediction; pharmacokinetics;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：21 / 21
页数：1
相关论文
共 50 条
  • [41] Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug-Drug Interactions
    Ly, Justin Q.
    Messick, Kirsten
    Qin, Ann
    Takahashi, Ryan H.
    Choo, Edna F.
    [J]. MOLECULAR PHARMACEUTICS, 2017, 14 (05) : 1754 - 1759
  • [42] Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib
    Cardona, Panli
    Dutta, Sandeep
    Houk, Brett
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (07): : 810 - 818
  • [43] A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4
    Templeton, Ian
    Ravenstijn, Paulien
    Sensenhauser, Carlo
    Snoeys, Jan
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2016, 37 (01) : 15 - 27
  • [44] Lack of venlafaxine CYP3A4 inhibitory effects on oral and IV model substrates
    DeVane, L
    Donovan, J
    Liston, H
    Markowitz, J
    Risch, C
    Willard, L
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S229 - S230
  • [45] CYP3A4-based drug–drug interaction: CYP3A4 substrates’ pharmacokinetic properties and ketoconazole dose regimen effect
    Xavier Boulenc
    Olivier Nicolas
    Stéphanie Hermabessière
    Isabelle Zobouyan
    Valérie Martin
    Yves Donazzolo
    Céline Ollier
    [J]. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41 : 45 - 54
  • [46] ASSESSMENT OF A BASIC MODEL FOR PREDICTING POTENTIAL CLINICAL DRUG INTERACTIONS MEDIATED BY CYP3A4 INHIBITION.
    Qosa, H.
    Avaritt, B.
    Volpe, D.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S43 - S43
  • [47] Screening for CYP3A4 metabolism and inhibition using a cocktail of Vivid® fluorogenic substrates
    Trubetskoy, OV
    Marks, BD
    Larson, GA
    [J]. DRUG METABOLISM REVIEWS, 2003, 35 : 125 - 125
  • [48] Quantitative prediction of CYP3A-mediated drug interactions.
    Kimura, RE
    Chen, YC
    Jiyamapa-Sherna, VA
    Hamman, MA
    Hall, SD
    Galinsky, RE
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P16 - P16
  • [49] Mechanism-based inhibition of CYP3A4 and CYP3A5 by seven inhibitors.
    Patki, KC
    von Moltke, LL
    Greenblatt, DJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P83 - P83
  • [50] The impacts of CYP3A4 genetic polymorphism and drug interactions on the metabolism of lurasidone
    Li, Qingqing
    Wang, Jing
    Wang, Zheng-lu
    Shen, Yuxin
    Zhou, Qi
    Liu, Ya-nan
    Hu, Guo-xin
    Cai, Jian-ping
    Xu, Ren-ai
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2023, 168
12345